Purchase this article with an account.
H. Kashiwagi, H. Tsuji, H. Obata, S. Suzuki, M. Noda, S. Ideta, Y. Nakamura, T. Kojima, K. Shimizu; A Review of One Hundred Five Cases of Ocular Tumors in Shizuoka Cancer Center in Japan . Invest. Ophthalmol. Vis. Sci. 2006;47(13):4690.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Shizuoka Cancer Center(SCC) was established in September 2002. The hospital has 500 beds, a Hospice, a Proton Beam Center, PET, and situated 100km west from Tokyo. We summarize our experiences in one hundred five ocular tumors that have increased in incidence and report a few representative cases.
A Retrospective review of the records of one hundred five patients(105 cases) who had ocular tumors in SCC between September 2002 and November 2005.
The patients’ ages ranged between 8 and 91 years (mean 59.27 years); 57 males and 48 females, 60 cases were malignant and 45 cases were benign. Orbital tumors were found in 56 cases: primary tumors(38) , secondary tumors(13) , metastatic tumors(5) . Many of primary orbital tumors were MALT lymphoma(10) , hemangiomas(4) , meningiomas(3) . Five maxillary sinus carcinomas were popular in the secondary orbital tumors. Origins of tumor’s matastasis in orbit were breast cancer, lung cancer, colon cancer, gastric cancer. There were 14 cases of eyelid tumors, 15 cases of conjunctival tumors. Eye lid tumors included sebaceous gland carcinomas(5) , basal cell carcinomas(4) , etc. Conjunctival tumors included squamous cell carcinomas(4) , papilloma(2) , hemangioma(2) , etc. Number of intraocular tumors were 15 cases: metastasis of cancers(6) , malignant melanomas(5) , retinal hemangiomas(2) , etc. Some rare cases were orbital fibrous tumor, conjunctival amyloidosis, Merkel carcinoma of eye lid, malignant chordoma of ethmoidal sinus, and two had paraneoplastic syndrome.
In this review, the common ocular tumors were MALT lymphomas in orbit(9.7%), sebaceous gland carcinomas of eyelid(4.7%).Ocular tumors will be increasing in number in the hospital specialized for cancers. Further summary including outcome analysis would be presented at the future ARVO.
This PDF is available to Subscribers Only